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Abstract
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Rapid classification and detection of SARS-CoV-2 variants have been critical in comprehending
the virus's transmission dynamics. Clinical manifestation of the infection is influenced by
comorbidities such as age, immune status, diabetes, and the infecting variant. Thus, clinical
management may differ for new variants. For example, some monoclonal antibody treatments
are variant-specific. Yet, a U.S. Food and Drug Administration (FDA)-approved test for detecting
the SARS-CoV-2 variant is unavailable. A laboratory-developed test (LDT) remains a viable
option for reporting the infecting variant for clinical intervention or epidemiological purposes.
Accordingly, we have validated the Illumina COVIDSeq assay as an LDT according to the
guidelines prescribed by the College of American Pathologists (CAP) and Clinical Laboratory
Improvement Amendments (CLIA). The limit of detection (LOD) of this test is Ct<30 (~15
viral copies) and >200X genomic coverage, and the test is 100% specific in the detection
of existing variants. The test demonstrated 100% precision in inter-day, intra-day, and intralaboratory reproducibility studies. It is also 100% accurate, defined by reference strain testing and
split sample testing with other CLIA laboratories. Advanta Genetics LDT COVIDSeq has been
reviewed by CAP inspectors and is under review by FDA for Emergency Use Authorization.
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1.

Introduction
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Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2 is the etiological agent of
COVID-19, which is associated with mild respiratory symptoms in most infections.
However, for patients with underlying medical conditions, comorbidities, and advanced
age, COVID-19 may lead to severe illness. The primary route of SARS-CoV-2 transmission
between humans is the respiratory route, including droplets of saliva or discharge from
infected patients. Diagnosis of COVID-19 relies on detecting SARS-CoV-2 viral RNA
from a nasopharyngeal or oropharyngeal specimen [1]. However, the rapid emergence
of several variants with higher virulence and infectivity has provoked repeat waves of
the deadly pandemic in many countries and raised anxieties about vaccine efficacy and
diagnostic accuracy [2]. Rapid classification and tracking of emerging variants are critical
for understanding the transmission dynamics of this disease and developing strategies for
severing the transmission chain. Next-Generation Sequencing (NGS) remains the tool of
choice for whole-genome analysis and deciphering new mutations [3]. Within a relatively
short period, SARS-CoV-2 has acquired several mutations resulting in different virus
variants. In December 2020, the United Kingdom reported a SARS-CoV-2 variant of
concern (VOC), lineage B.1.1.7, detected in over 30 countries and is more efficiently
transmitted than other SARS-CoV-2 variants. Thus, the pandemic strikes in several phases
of outbreaks in different parts of the world [4]. Currently, the virus continues to be a
global agent of infection. The highly mutagenic nature of SARS-CoV-2 assaulted many
countries with second or third waves of the outbreak [5, 6]. Mutations with higher
transmissibility, a more intense disease state, and less likely to respond to vaccines or
treatments have been classified by the World Health Organization (WHO) as Variants of
Concern. Recent epidemiological reports released by WHO indicated five VOCs: 1) B.1.1.7
(Alpha) in December 2020; 2) B.1.351 (Beta) in December 2020; 3) P.1 (Gamma) in
January 2021; 4) B.1.617.2 (Delta) in December 2020, and 5) B.1.1.529 (Omicron) (https://
www.who.int/en/activities/tracking-SARS-CoV-2-variants/). The receptor-binding domain
(RBD) of coronavirus increases its capacity to strike in several outbreak phases in different
parts of the world [7]. More recently, South Africa reported a new SARS-CoV-2 variant
to the WHO. Omicron (B.1.1.529) was first detected in specimens collected in Botswana
and designated as the fifth VOC [8] (https://www.who.int/activities/tracking-SARS-CoV-2variants). Several variant-specific treatment options have been approved by the U.S. Food
and Drug Administration (FDA), including Bebtelovimab, a monoclonal antibody for the
treatment of COVID-19 that retains activity against the omicron variant. However, a
recent study shows that the effectiveness of mRNA vaccines is reduced against all three
subvariants of omicron [9]. Several other studies have reported a substantial decrease
in neutralizing antibody titers after vaccination against all coronavirus variants. [10, 11].
Reduced neutralizing activity against the B.1.1.7 (Alpha), B.1.35 (Beta), and P.1 (Gamma)
strains have been reported among the Pfizer-BioNTech vaccinated populations [12]. Another
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study investigated the neutralization of antibodies elicited by Novavax NVX-CoV2373,
a protein subunit vaccine, and that of mRNA-1273 by Moderna against the California
variant B.1.429 and B.1.351 pseudoviruses. The small-scale study of 63 volunteers similarly
revealed the reduction in neutralization abilities of antibodies elicited by both vaccines. The
most drastic reduction, up to a 9–14 times decrease in neutralization compared to D614G,
was observed with B.1.351 pseudovirus, where the antibodies were 2–3 times less sensitive
against the B.1.429 variant pseudovirus [13]. SARS-CoV-2 is likely to continue to evolve,
and the next strain may have a strain-specific etiology requiring strain information for
patient care. In the present situation, most infections are attributed to a single sublineage.
However, new lineages are likely to emerge and replace existing circulating lineages. Several
PCR-based assays are available for the detection of the known variants. These assays are
not designed to detect unknown infected variants [14]. Unlike the PCR-based test, this
NGS-based assay can detect new variants as they emerge. And because lineage variance has
potential implications for virulence and infectivity, validation of NGS assays that proactively
identify mutagenic variants enables these test results to be used in clinical applications
when warranted. Furthermore, this Illumina COVIDSeq assay is used for epidemiological
surveillance globally. Still, the validation of the assay as a Laboratory Developed Test
(LDT) is required to use variant information for clinical decision-making. For example,
variant-specific monoclonal antibody therapies have been emphasized by the National
Institutes of Health (NIH) COVID Treatment Guidelines Panel and the FDA, recommending
against the use of bamlanivimab and etesevimab (administered together) and REGEN-COV
(casirivimab and imdevimab) because of significantly reduced activity. Consequently, we
report the validation of the NGS-based test to identify the existing and emerging variants of
SARS-CoV-2 [16]. This study has benchmarked the validation process for using the variant
information in clinical management as required by CLIA. Although the Illumina COVIDSeq
assay has been approved for emergency use authorization (EUA) for the diagnosis of
COVID-19; the assay has not been approved for variant detection. We validated the Illumina
COVIDSeq assay according to CLIA/CAP requirements for LDT, and the validation report
has been submitted to the FDA for EUA, and reviewed by a team of CAP inspectors.
Accordingly, the COVIDSeq assay is qualified to diagnose SARS-CoV-2 variants of infected
individuals and can be deployed for monitoring the evolution of SARS-CoV-2 variants in
decentralized clinical laboratory settings.

Author Manuscript
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2.

Materials and Methods
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The workflow consists of the following procedures: RNA extraction, cDNA synthesis, target
amplification, library preparation, library pooling, sequencing, and analysis. Validation was
performed to achieve a high degree of accuracy and precision. Additional studies were
performed to test the effect of interference substances and sample stability.
2.1

Reference Strains of SARS-CoV-2 Variants
We used three reference strains of SARS-CoV-2, Omicron, Delta, and Wuhan. Complete
genome synthetic RNAs of these strains were obtained from BEI Resources.
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De-identified sample remnants from nasopharyngeal swabs were collected from the patients
who tested positive for SARS-CoV-2 PCR with RT-PCR at Advanta Genetics (https://
aalabs.com/) in Tyler, Texas. Samples were stored at −80°C until RNA extraction. The study
was exempted by IRB (Institutional Review Board) because only de-identified samples were
used.
2.3

RNA Extraction
Total RNA was extracted using the Roche MagNA Pure 96 System and Viral RNA Small
Volume Kits per the manufacturer’s (Port Scientific Inc. QC J3G 4S5 Canada) instructions.
Isolated RNA was frozen at −80°C until the library preparation.

2.4

Library Preparation and Sequencing

Author Manuscript
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The libraries were prepared using the Illumina COVIDSeq protocol (Illumina Inc, USA).
Briefly, total RNA was primed with random hexamers, and first-strand cDNA was
synthesized using reverse transcriptase. The SARS-CoV-2 genome was amplified using the
two sets of primers (COVIDSeq Primer Pool-1 & 2) provided by Illumina, but the primer
sequences have not been disclosed by the manufacturers. Primers are not mutation specific
but designed to amplify the entire genome. PCR amplicons were tagmented using the
EBLTS (Enrichment BLT), which is a process that fragments and tags the PCR amplicons
with adapter sequences. Adaptor ligated amplicons were further amplified using the distinct
pre-paired 10 base pair Index 1 (i7) adapters and Index 2 (i5) adapters (IDT for IlluminaPCR Indexes Set 1) for each sample. The individual library was quantified using a Qubit
2.0 fluorometer (Invitrogen, Inc.) and pooled in equimolar concentration instead of equal
volume as recommended by Illumina. This additional step allowed us to achieve uniform
coverage of all the libraries in the pool and efficient use of a low throughput sequencing
instrument (MiniSeq®). A COVIDSeq positive control (Wuhan-Hu-1) and one no template
control (NTC) were processed with each batch of libraries. The final library pool was
again quantified using a Qubit 2.0 fluorometer (Invitrogen, Inc.) and a PCR-based library
quantification kit (Scienetix, USA). The final library pool was diluted to a 2 pM loading
concentration. Dual indexed paired-end sequencing with 75bp read length was carried out
using the HO flow cell (150 cycles) on the Illumina MiniSeq® instrument.
2.5

NGS Data Analysis

Author Manuscript

Illumina Basespace (https://basespace.illumina.com) bioinformatics pipeline was used for
sequencing QC, FASTQ generation, genome assembly, and identification of SARS-CoV-2
variants. Briefly, the raw FASTQ files were trimmed and checked for quality (Q>30) using
the FASTQ-QC application within the Basespace. QC passed FASTQ files were aligned
against the SARS-CoV-2 reference genome (NCBI Reference Sequence NC_045512.2)
using Bio-IT Processor (Version: 0x04261818). Then, DRAGEN COVID Lineage (Version:
3.5.4) application in Bbasespace was used for SARS-CoV-2 variant determination and
generating a single consensus FASTA file. Finally, single consensus FASTA was also
analyzed for lineage assignment using the web version of Phylogenetic Assignment of
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Named Global Outbreak Lineages (PANGOLIN) software (https://pangolin.cog-uk.io). Only
the consensus variants identified by both applications were used for further analysis.
2.6

Strain Typing of SARS-CoV-2 in the East Texas Region
We have applied the SARS-CoV-2 variant detection workflow established in this study for
strain typing of SARS-CoV-2 in the East Texas USA region over the course of the pandemic.
Representative samples collected at various po time during the pandemic (Aug 2020, July
2021, Dec 2021, April 2022, July 2022, and Sept 2022) were sequenced and analyzed for the
circulating variants in the region of interest.

3.

Results

Author Manuscript

The SARS-CoV-2 sequencing test was validated as LDT according to the guidelines
prescribed by the CAP and mandated by CLIA. Briefly, the limit of detection (LOD),
analytical accuracy, precision, and sample stability was established. The effect of carryover
and interference substances was also investigated.
3.1

Analytical Sensitivity/Limit of Detection

Author Manuscript

This assay is not intended to diagnose the SARS-CoV-2 infection but is meant for
discovering the SARS-CoV-2 variant from a patient previously diagnosed with a high level
(Ct<30) of SARS-CoV-2 infection. LOD of this assay was determined for two variables
needed for accurate results: 1) the lowest amount of input genomic material and 2) minimum
genomic coverage. For genomic material LOD, serial dilutions of an Omicron reference
variant were sequenced in triplicates, and the lowest input concentration resulting in the
correct variant detection is identified as LOD (Table-1). LOD for the test is defined as
Ct<30 (~15 copies/ul of RNA). LOD was further verified by sequencing 23 samples with
RNA input close to LOD (PCR Ct value ~30±2) and obtained 200X-1000X coverage;
variants for all the 23 samples were identified correctly. We have also analyzed the 26
additional samples from patients found positive during September 2022—all the samples
have Ct<30. We sequenced the 26 samples, including 10-fold and 100-fold dilutions of
three representative samples. We were able to identify the variant in all 26 samples and
endorse the application of the assay on current circulating strains post-vaccination. However,
the application of this test in asymptomatic or very low viral load (<150 viral genome/ul)
remains the limitation of the assay.

Author Manuscript

To determine the LOD regarding genomic coverage, we computed the depth of coverage (X
times) and percent genome coverage for all tested samples. The lowest genomic coverage
of >200X (Depth) and 90% genome coverage is required for successful detection variant
detection (Figure-1). Importantly, all 164/164 (100%) observations with a minimum of
90% genome coverage at a minimum of 200X resulted in the correct variant call after the
analysis.
3.2

Analytical Accuracy
Accuracy is a determination of the amount of systematic error in the system. The analytical
specificity of this assay is determined by re-sequencing the already sequenced reference

Arch Clin Biomed Res. Author manuscript; available in PMC 2022 December 30.

Carpenter et al.

Page 6

Author Manuscript

strains of the SARS-CoV-2 virus and the alignment of the resulting FASTQ files to the
available reference genome sequence using the BaseSpace (Illumina) tool. We tested 3
known SARS-CoV-2 variants; Wuhan-Hu-1, B.1.617.2 (Delta), and B.1.1.529 (Omicron)
in triplicates, and all the variants were identified correctly as expected. NGS does not use
analyte (i.e., SARS-CoV-2 variant) specific reagents to determine the correct variant but uses
whole genome analysis for discerning the variants. Therefore, the specificity of the variant
detection is considered 100% (Table 2).

Author Manuscript

Considering the limited availability of reference strains, we also re-sequenced the 6 samples
already sequenced by another reference laboratory (Fulgent Genetics) at extremely high
coverage (>30,000X), and variant identities were compared between two observations. A
total of 6 samples were sequenced at Fulgent Genetic and Advanta Genetics. All 6 samples
were identified to carry identical variants by both laboratories implicating 100% accuracy
in inter-laboratory testing (Table-3). The average sequencing coverage at Fulgent Genetics
is 34560.5X compared to 174.3X at Advanta. Interestingly, variants of 3 samples sequenced
at >50,000 coverage were correctly identified by only 200X coverage. With pre-pooling
quantification, we achieved higher sequencing efficiency without compromising the test
accuracy. Such higher efficiency is critical for the cost-effective application of this test in
limited-resourced and de-centralized laboratory settings.
3.3

Precision

Author Manuscript

The precision of a measurement system, related to reproducibility and repeatability, is the
degree to which repeated measurements under unchanged conditions show the same results.
Inter-day precision is determined by sequencing 9 samples of known genomic variants over
three days. Nine samples were tested in three rounds of library preparations, sequencing,
and data analysis. The identity of the variant detected across the three runs was compared.
All 9 samples were identified correctly across the three sequencing instances implicating
100% precision across the 27 observations. Inter and intra-day precision was determined
by testing 6 clinical samples (near LOD) in triplicate during three rounds of library
preparations, sequencing, and data analysis. The identity of the variant detected across
the three runs was compared. Three samples that failed the pre-defined QC (library yield,
reads, coverage, etc.) were excluded from the precision. Over three days, the remaining
51/54 observations were in 100% concordance for triplicate testing. All 6 samples were
identified as the same variant in triplicate testing within a single batch implicating 100%
intra-run precision (Supplementary-2). Likewise, the same samples resulted in identical
variants when tested in three distinct batches of library preparation, sequencing, and data
analysis (Supplementary-3). Thus, inter-day precision was also determined as 100%.

Author Manuscript

3.4

Stability Study
The stability of clinical samples at different temperatures was tested to simulate the
temperature conditions during transportation. Samples identified as Omicron (n=3) and
Delta (n=1) were placed at 4 different temperatures [Freezer (−20°C); Refrigerator (2-8°C);
Room Temp (~25°C); Elevated Temp (~50°C)] to mimic the possible environmental
conditions during the transportation. Samples were left for up to 7 days under these
temperature conditions. Samples were retrieved at 24 hours, 3 days, and 7 days intervals,
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and RNA was extracted and stored at −80°C. RNA from all the samples in the stability study
was tested in a single library preparation and sequencing batch. We were able to sequence
and identify the SARS-CoV-2 variant of the samples kept at 20°C, 2-8°C, ~25°C, and
~50°C for 24 hours and 3 days. However, samples placed in elevated temperature conditions
resulted in low-quality sequencing data, which did not result in variant detection. Overall,
samples kept at an elevated temperature (~50°C) over 3 days were unsuitable for variant
detection by whole-genome sequencing (WGS). All the samples used for the stability study
were of viral load close to LOD.
3.5

Freeze-Thaw Stability Study

Author Manuscript

Extracted RNA was subjected to 2 and 3 freeze-thaw cycles, and RNA was processed
in single Library preparation. RNA sample after 2 freeze-thaw cycles fail the pre-defined
sequencing QC and could not be used for variant detection. Although sample or RNA
storage conditions are unlikely to change the SARS-CoV-2 variant, >3 days of storage
at high temperature (~50°C) may cause the SARS-CoV-2 variant testing to fail or result
inconclusive because of compromised data quality. Likewise, >2 freeze-thaw cycles for
RNA also compromised the sequencing data quality. Thus, samples for SARS-CoV-2 variant
detection should be kept at 4°C for 7 days and stored at −20°C for the long term (Table-4).
3.6

Role of Interference Substances
Clinical specimens may contain biological or non-biological substances which may interfere
with the testing process. We spiked the commonly used nasal sprays into the clinical
specimen and tested the sample with and without the external substance. None of the tested
substances altered the results or compromised the data quality (Data not shown).

Author Manuscript

3.7

Epidemiological Survey of East Texas, US
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We have also applied Advanta Genetics LDT COVIDSeq to investigate the evolution of
SARS-CoV-2 in the East Texas region during the pandemic. We identified a greater genomic
diversity in early pandemics before identifying variants of Concern. We identified the
SARS-CoV-2 variant (B.1, B.1.126, B.1.2, B.1.234, B.1.243, B.1.564, B.1.574, B.1.602)
among the samples collected in July 2020. All of these variants were categorized as nonVOC by the WHO. Diverse non-VOC strains were initially replaced by the Delta variant
(100%) in July-Aug 2021. Omicron (58%) and Delta (42%) variants were co-circulating
during Dec 2022; Delta was completely replaced by the Omicron variant by December
2021. Omicron BA.2 (79%) was the dominant variant during April 2022, which was again
replaced by BA.5 (78%) in September 2022. (Figure-2). Thus, continuous monitoring is
warranted to keep the pandemic from returning to the scale seen earlier by identifying the
vaccine escape or target dropout in diagnostic testing. All the SARS-CoV-2 whole-genome
sequences generated in this study were submitted to GISAID (https://www.gisaid.org)
database (Supplementary Table-1), [17].

4.

Discussion
WHO has been classifying the SARS-CoV-2 variant into various categories according to
their possible clinical implication and public health concern. Several technologies have
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Interestingly, 3 of these samples were sequenced at >50,000X coverage by Fulgent
Genetics, and the same samples were sequenced at 200-300X coverage at Advanta Genetics.
Results from both sequencings were in 100% concordance, suggesting that such high
sequencing depth is unnecessary for routine variant detection. The introduction of prepooling quantification and equimolar pooling enabled us to achieve uniform distribution of
sequencing reads across the samples in the pool, resulting in more efficient sequencing. This
approach particularly important in de-centralized reference laboratories which do not have
access to high throughput instruments such as Illumina HighSeq or NovSeq. We were able
to sequence up to ~30 samples in a single MiniSeq run, reducing the cost of sequencing
(excluding library preparation) to ~ $30/sample. The genome sequences available from
public databases may have been generated using different sequencing chemistries or
platforms, which might yield different error rates; therefore, the inter-laboratory study

Author Manuscript

been adopted for SARS-CoV-2 variant detection, but NGS remains the gold standard
because of comprehensive genomic analysis [18, 19]. In June 2020, the US FDA granted
EUA for Illumina’s NGS test for COVID-19 diagnosis. However, the test has not been
widely adopted for diagnosis because RT-PCR is much cheaper and easy to implement in
the unprecedented need for SARS-CoV-2 testing. Although RT-PCR remains the method
of choice for routine diagnosis, Illumina COVIDSeq protocol has been instrumental in
outbreak investigation and surveillance throughout the pandemic [20]. Several laboratories
worldwide use WGS for high throughput surveillance communicated by health organizations
[21]. The Delta variant has been associated with greater transmissibility and higher viral
RNA loads in both unvaccinated and fully vaccinated individuals [22]. WGS has also
identified the potential compromise vaccine effectiveness against the Omicron variant [23].
The emergence of SARS-CoV-2 variants with significantly different clinical implications
accentuates the need for variant detection, especially for immunocompromised patients.
Additionally, because some monoclonal antibody treatments are variant-specific, timely
identification of the infecting SARS-CoV-2 variant may influence decision-making and
treatment. Currently, there is no FDA-approved SARS-CoV-2 variant detection test for
diagnosing individual patients. Thus, LDT remains the only viable option to leverage NGS
methods for SARS-CoV-2 variant diagnosis. This virus is predicted to mutate continuously,
and the evolution of variants with significantly different clinical interventions cannot be
ruled out [5]. This study established the WGS workflow for detecting SARS-CoV-2 variants
according to CLIA guidelines for LDTs. The importance of reference materials for the
validation and QC of wet-lab and dry-lab WGS processes is well established [24]. However,
unlike human genomics [25], there is no well-established resource of reference materials for
the validation of such genetic variant detection tests. Therefore, we obtained three reference
strains (Wuhan, delta, and Omicron) of SARS CoV-2 for accuracy study, and all three
variants were correctly identified in repeated testing. The Wuhan strain of SARS-CoV-2 has
been accepted as the reference strain [26]. Therefore, all the sequences generated during this
study were aligned against the Wuhan strain genome [26]. Although more than a million
SARS-CoV-2 genomes have been sequenced [27], a limited number of well-characterized
reference genomic materials are available. To overcome this limitation, we re-sequenced 6
samples already sequenced by another laboratory (Fulgent Genomics), and the sequencing
results were in 100% concordance.

Author Manuscript
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was of particular interest because the reference laboratory used a different instrument for
sequencing. Overall, we achieved high accuracy, reproducibility, repeatability, diagnostic
(variant detection) sensitivity, and specificity of 100%, which exceeds the 90% threshold
for LDT performance parameters per CLIA requirements. These findings agree with other
reports of 93% to 100% accuracy in WGS identification and subtyping for other pathogens
[28, 29]. We determined the LOD as 90% genome sequenced at >30X depth and >200X
median depth of coverage. The LOD study did not consider coverage for individual single
nucleotide polymorphisms (SNP) because an SNP combination determines the SARS-CoV-2
genomic variant. LOD, in terms of minimum genomic copies, was established at ~15
copies/μL going into the sequencing reaction. This assay can identify the genomics variant
from the lower viral RNA input, but this is the lowest input tested during this validation.
Vaccination has reduced hospitalization and deaths in COVID cases, but the viral load
(10E+05 to 10E+08 genomic copies/ml) in breakthrough cases remains high enough for
detection by this assay [15]. Interestingly, only infectious viral load (VL) was lower in
fully vaccinated Omicron BA.1-infected individuals compared to vaccinated Delta-infected
individuals, indicating variant-specific response to the vaccines. A reduced infectious VL)
was observed only in boosted but not fully vaccinated individuals compared to unvaccinated
individuals [15]. Still, genomic copies/ml of the sample remain very high (~million genomic
copies/ml), significantly above the LOD of this test, implicating that test will be useful
in a post-vaccination era. We found some of the CLIA-defined LDT performance criteria
difficult to apply. For example, CLIA would allow for up to 10% of base calls to be incorrect
for accuracy determination, which, in the case of the ~30,000 bp SARS-CoV-2 genome,
would mean ~3,000 inaccurate bases, which could lead to false variant detection. We
accepted a minimum of 90% genome coverage and >200X median depth, but detection of
the genomic variant was considered for final accuracy calculations. Because one erroneous
SNP is unlikely to change genotyping conclusions in most instances, analysis was limited
to overall variant detection using the default parameters for ease of implementation in the
clinical laboratory. We also did not test the recommended 20 replicates to determine the
LOD because this test is not intended to detect an analyte but the variations (genomic
variant) in the analyte. Acceptable depth of coverage has been identified as 10X coverage
of >90% of the genome. Low input of the RNA or lower reads will not meet these
criteria. Therefore, false or undetermined variants are unlikely to be reported in low-input
samples. Implementing a continuous performance measurement plan via an internal or
external PT program is required to successfully integrate any test in the clinical laboratory
(CAP Checklist 2021; https://www.cap.org). A set of reference SARS-CoV-2 variants is
amenable to internal and external quality assurance testing. We assessed the entire workflow
in preliminary internal PT by re-testing blind samples and inter-personnel reproducibility
(details not shown). WGS is a dynamic technology evolving rapidly; therefore, our validated
pipeline is unlikely to remain static. Re-validation provision is crucial for the seamless and
timely implementation of changes to wet-lab reagents or the analysis pipeline. We have
introduced a provision for reagent verification at each lot change by re-testing samples
in triplicate. Likewise, raw sequencing data will be re-analyzed with an updated analysis
pipeline, and the accuracy of variant detection will be verified. DRAGEN COVID Lineage
variant pipeline has been updated during the validation, and the variant identified by the two
versions are in 100% concordance (data not shown). In general, WGS diagnosis reports are
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complex, and the format could pose challenges for the end-user. We adopted a simple format
already used for SARS-CoV-2 diagnosis, and an updated report with the variant information
will be issued if the reflex testing for variant detection is requested. This study possesses
certain limitations. First, only a limited number of WGS-based assays were included in the
validation study based on the limited application of this test for clinical decision-making.
Second, we could not establish this test's clinical sensitivity and specificity because the
clinical presentation of the patients infected with different variants is not distinct [30].
Moreover, the study could not acquire clinical samples of every lineage to demonstrate
accuracy. However, CLIA and CAP regulations do not require validation of each mutation
in the case of the mutation detection assay. For example, genomic mutation detection assays
are commonly used in oncology. Likewise, we demonstrated the accuracy of the assay by
testing three major variants. The vaccination status of the samples was not available to
compare the application of the assay in the post-vaccination era. Although the vaccination
status of the individual patient was not available, we tested >100 patient samples in the postvaccination era to demonstrate that the test remains applicable to the vaccinated population.
We could not try the test’s clinical utility because that would require enrolling the patients
infected with different variants and administering variant-specific treatment. Since their
inception, most NGS-based testing has been limited to large medical centers, public health
laboratories, or centralized genomics facilities with rather large infrastructures. The recent
pandemic has accentuated the importance of de-centralized independent laboratories. For
example, Advanta Genetics has served East Texas by testing > 500,000 SARS-CoV-2
samples. Thus, this validation can be used as guidelines for other small laboratories with
NGS capacities if a need for SARS-CoV-2 variant detection arises. Although inevitable
in the early stages, de-centralized NGS testing presents several challenges, such as high
cost and turnaround time because of low volume testing. However, de-centralized and rapid
testing for circulating SARS-CoV-2 variants may become crucial for clinical management
and tracking the transmission at the local and regional levels. Sequencing cost in terms
of dollars/gigabases has plummeted with high throughput instruments such as Illumina
NovaSeq. However, such an instrument alone costs ~ a million dollars. It would require
batching of ~30,000 samples to achieve the highest efficiency, which is not practical for
independent laboratories, potentially leaving a gap in underserved communities.

Author Manuscript

This study introduces pre-pooling normalization to improve sequencing efficiency, which
is crucial for smaller laboratories with low throughput sequencers. The emergence of
more affordable sequencers such as Oxford Nanopore (Starting cost of $10,000) enriches
the opportunity for de-centralized genomic testing if a variant with distinct clinical
needs emerges or for any future pandemic. We have demonstrated that NGS services,
including clinical testing, could be delivered locally with well-defined quality metrics at an
affordable cost. Global NGS data aggregators that emerged from this pandemic have been
helpful for analysis support needed for resource-limited laboratories (https://www.gisaid.org/
collaborations/enabled-by-hcov-19-data-from-gisaid/), but sequencing infrastructure remains
centralized mainly [31]. The local-delivery model would also be more responsive to the
target clients' needs and enhance the adoption of NGS across health care systems. We have
demonstrated the application of this approach in the East Texas region and tracked the
variant evolution throughout the pandemic. An alternate hybrid model has been proposed
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with complementary central and local services to balance the need for speed and investment
[32]. The FDA Genome Tracker network for tracking foodborne pathogens and the Centers
for Disease Control and Prevention (CDC) Advanced Molecular Detection (AMD) initiative
for improving infectious disease surveillance are existing hybrid models in the United States
[33, 34]. Notably, there are still significant challenges to implementing comprehensive
WGS services locally [35, 36]. This study has established the performance specifications
for NGS-based SARS-CoV-2 variant detection according to CAP and CLIA guidelines.
We anticipate that the COVIDSeq LDT validation framework presented in this study, in
synergy with increasingly accessible analysis support, will advance the localization of
comprehensive NGS services in independent clinical laboratories. We have benchmarked
quality assurance and quality control measures for implementing such testing and a
simplified reporting format for end-users with limited NGS understanding. The study
also affirmed the application of de-centralized NGS testing for clinical and public health
applications with any resurgence of COVID-19 or the next infectious disease outbreak.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Data Availability
GISAID Identifier: EPI_SET_20220715vh doi: 10.55876/gis8.220715vh
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All genome sequences and associated metadata in this dataset are published in GISAID’s
EpiCoV database. To view the contributors of each sequence with details such as accession
number, Virus name, Collection date, Originating Lab and Submitting Lab, and the list of
Authors, visit 10.55876/gis8.220715vh
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Figure 1:

Limit of Detection (LOD): Median genomic coverage (X-times) and minimum % length of
the genome covered >30X times were computed, and the minimum coverage required for
obtaining the accurate SARS CoV-02 lineage was defined as LOD.
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Figure 2:

Evolution of SARS-CoV-2 variants in East Texas over the course of the Pandemic.
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Limit of Detection: Four serial dilutions of Omicron strain were sequenced in duplicate, and the lowest viral
RNA input, which resulted in accurate variant detection, was accepted as LOD for the test.
ACSQ Observed Linieage
Pango
Lineage

Sample ID

Relative
Copy/ul

PCR Ct Value
N1

N2

Median
Coverage

Coverage
>= 30x

Pango
Lineage

WHO label

ACSQ4-19

1.48E+04

26.16

26.37

663

96.79%

BA.1

Omicron

ACSQ4-19 (1:10)

1.48E+03

29.87

30.15

690

95.18%

BA.1

Omicron

ACSQ4-19 (1:100)

1.48E+02

33.24

33.54

504

94.46%

BA.1

Omicron

ACSQ4-19 (1:1000)

1.46E+01

36.54

35.47

586

91.29%

BA.1

Omicron

ACSQ4-19

1.48E+04

26.16

26.37

533

95.87%

BA.1

Omicron

ACSQ4-19 (1:10)

1.48E+03

29.87

30.15

489

94.89%

BA.1

Omicron

ACSQ4-19 (1:100)

1.48E+02

33.24

33.54

745

94.97%

BA.1

Omicron

ACSQ4-19 (1:1000)

1.46E+01

36.54

35.47

736

93.61%

BA.1

Omicron

ACSQ9-1A

1.48E+03

29.83

28.36

1597

94.25%

BA.4.6

Omicron

ACSQ9-1A (1:10)

1.48E+02

33.16

31.69

330

82.33%

BA.4.6

Omicron

ACSQ9-1A (1:100)

1.46E+01

36.49

35.02

ACSQ9-4A

1.58E+03

27.4

26.17

2300

96.89%

BA.5.2.1

Omicron

ACSQ9-4A (1:10)

1.58E+02

30.73

29.5

1635

92.93%

BA.5.2.1

Omicron

ACSQ9-4A (1:100)

1.58E+01

34.06

32.83

514

88.59%

BA.5.2.1

Omicron

ACSQ9-23

1.48E+04

26.65

23.71

3355

99.46%

BA.2.3

Omicron

ACSQ9-23 (1:10)

1.48E+03

29.98

27.04

2798

98.52%

BA.2.3

Omicron

ACSQ9-23 (1:100)

1.48E+02

33.31

30.37

2051

95.68%

BA.2.3

Omicron

BA.1

BA.1
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BA.4.6

BA.5.2.1

BA.2.3

Not detected
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Accuracy of the test is determined by sequencing 3 reference strains of the SARS-CoV-2 virus.
Reference Lineage
Sample ID

Detected Lineage

Median
Coverage

Pango
Lineage

WHO
label

Median
Coverage

Pango
Lineage

WHO
label

Concordance

Wuhan (1500cp/ul)

NA

A1

Non-VOC

1167

A1

Non-VOC

YES

Wuhan (150cp/ul)

NA

A1

Non-VOC

2289

A1

Non- VOC

YES

Omicron (1500cp/ul)

NA

B.1.1.529

Omicron

1372

B.1.1.529

Omicron

YES

Omicron (150cp/ul)

NA

B.1.1.529

Omicron

829

B.1.1.529

Omicron

YES

Delta (1500cp/ul)

NA

B.1.617.2

Delta

663

B.1.617.2

Delta

YES

Delta (150cp/ul)

NA

B.1.617.2

Delta

533

B.1.617.2

Delta

YES
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Comparative genome sequencing and variant calling results obtained from two different laboratories.

Sample
ID

Fulgent Genetics*

Advanta Genetics
Concordance

Median
Coverage

Pango
Lineage

WHO
label

Median
Coverage

Pango
Lineage

WHO
label

ACSQ1-2

77387.8

AY.4

Delta

214

AY.25

Delta

YES

ACSQ1-3

341.6

AY.3

Delta

228

AY.3

Delta

YES

ACSQ1-4

54823.9

AY.3

Delta

222

AY.3

Delta

YES

ACSQ1-5

2860.5

AY.4

Delta

218

AY.3

Delta

YES

ACSQ1-6

69088.9

B.1.617.2

Delta

258

B.1.617.2

Delta

YES

ACSQ1-7

2860

AY.3

Delta

106

AY.3

Delta

YES

*

Variant from AY4 to AY 25 were reported as AY4 in the sequencing results obtained from the Fulgent Genetics.
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Samples stored in simulated environmental conditions mimicking the possible transportation and storage
temperature were sequenced to identify acceptable sample storage conditions.
Sample-ID

Temp

Time

Median
Coverage

Coverage >= 30x

1256.5

98%

Author Manuscript

ACSQ4-1

Freezer (−20C)

24hr

ACSQ4-9

Freezer (−20C)

48hr

1286

98%

ACSQ5-1

Freezer (−20C)

72hr

588.5

96%

ACSQ5-9

Freezer (−20C)

7days

524

95%

ACSQ4-3

Room Temp (~25C)

24hr

1284.5

97%

ACSQ4-11

Room Temp (~25C)

48hr

1254.5

97%

ACSQ5-3

Room Temp (~25C)

72hr

643

96%

ACSQ5-11

Room Temp (~25C)

7days

458.5

95%

ACSQ4-2

Refrigerator (2-8C)

24hr

998.5

94%

ACSQ4-10

Refrigerator (2-8C)

48hr

1086.5

96%

ACSQ5-2

Refrigerator (2-8C)

72hr

537

94%

ACSQ5-10

Refrigerator (2-8C)

7days

477

94%

ACSQ4-4

Elevated Temp (~50C)

24hr

866.5

94%

ACSQ4-12

Elevated Temp (~50C)

48hr

1029

96%

ACSQ5-4

Elevated Temp (~50C)

72hr

363

91%

ACSQ5-12

Elevated Temp (~50C)

7days

Low Coverage

ACSQ5-16

Elevated Temp (~50C)

7days

Low Coverage
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